-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Pacific Biosciences, Lowers Price Target to $2.7

Benzinga·11/09/2026 21:07:53
Listen to the news
UBS analyst Doug Schenkel maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral and lowers the price target from $3.05 to $2.7.